Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.31+1.28 (+12.76%)
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Keros Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Keros Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -698.0%. For fiscal 2025 it was 27.7%, against -112543.7% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.7% | +112571.4 |
| FY2023 | Dec 31, 2023 | -112543.7% | −112263.2 |
| FY2021 | Dec 31, 2021 | -280.5% | −174.8 |
| FY2019 | Dec 31, 2019 | -105.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -80865.6% | −80937.6 |
| Q4 FY2025 | Dec 31, 2025 | -7702.6% | +24783.4 |
| Q3 FY2025 | Sep 30, 2025 | -108.9% | +540891.1 |
| Q2 FY2025 | Jun 30, 2025 | -219.2% | −194.8 |
| Q1 FY2025 | Mar 31, 2025 | 72.0% | +15613.0 |
| Q4 FY2023 | Dec 31, 2023 | -32486.0% | −32376.9 |
| Q3 FY2023 | Sep 30, 2023 | -541000.0% | −540907.0 |
| Q4 FY2021 | Dec 31, 2021 | -24.3% | +81.7 |
| Q2 FY2021 | Jun 30, 2021 | -15541.0% | −15426.7 |
| Q4 FY2019 | Dec 31, 2019 | -109.1% | – |
| Q3 FY2019 | Sep 30, 2019 | -93.0% | – |
| Q2 FY2019 | Jun 30, 2019 | -106.0% | – |
| Q1 FY2019 | Mar 31, 2019 | -114.3% | – |
See a number that looks wrong?